Q4 2024 BioMarin Pharmaceutical Inc Earnings Call Transcript
Key Points
- Biomarin Pharmaceutical Inc (BMRN) reported a record growth and profitability in 2024, with a topline growth of 18% year over year.
- The company achieved a significant expansion in non-GAAP operating margin by over 900 basis points and a 69% increase in non-GAAP diluted earnings per share.
- VOXZOGO for achondroplasia showed impressive growth of 56% year over year, with plans to expand into hypochondroplasia and other skeletal conditions.
- The enzyme therapy business grew by 9% in the fourth quarter, nearing $2 billion in annual revenues, supporting a high single-digit CAGR outlook.
- Biomarin's strategic pipeline prioritization led to advancements in promising candidates like BMN 351 for Duchenne Muscular Dystrophy and BMN 333, with early clinical data expected later this year.
- Despite strong growth, VOXZOGO's growth rate is expected to decelerate due to the law of large numbers as the revenue base increases.
- The enzyme therapy business experienced unusual high contributions from ALDURAZYME in 2024, which may not be sustainable in 2025.
- Non-GAAP SG&A expenses increased due to a bad debt reserve and higher commercialization expenses, impacting overall profitability.
- There is a potential risk of competition in the achondroplasia treatment market, which could affect VOXZOGO's market share.
- The company faces challenges in expanding patient access and awareness, particularly in the US, where a significant portion of eligible patients remain untreated.
Ladies and gentlemen, thank you for standing by and welcome to the BioMarin Pharmaceuticals fourth quarter and full year's 2024 conference call. (Operator Instructions)
As a reminder, today's call is being recorded. I will now hand today's call over to Traci McCarty, Group Vice President, Investor Relations. Please go ahead.
Thank you, operator. To remind you, this non-confidential presentation contains forward-looking statements about the business prospects of BioMarin's Pharmaceutical Inc., including expectations regarding BioMarin's financial performance, commercial products, and potential future products in different areas of therapeutic research and development.
Results may differ materially depending on the progress of BioMarin's product programs, actions of regulatory authorities, availability of capital, future actions in the pharmaceutical market, and developments by competitors, and those factors detailed in BioMarin's filings with the Securities
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
